The RSA Group was delighted to partner with Biotec Pharmacon to secure the appointment of Mr. Christian Jørgensen as their new Chief Executive Officer.
Biotec Pharmacon ASA is a Norway-based biopharmaceutical company that develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The Company focuses on new solutions within wound care, cancer therapies and other immune related disease areas. It has a portfolio of patents covering marine gene products for the molecular biology sector, and products with potentials within the pharmaceutical sector, such as beta-1,3/1,6-glucan formulations.
Thomas Schleimer, Partner with The RSA Group commented: “We are pleased to have been selected to support Biotec Pharmacon sourcing their new CEO. Our deep specialisation in Life Sciences enabled us to define the value proposition and attract executives with a background in MedTech and wound care but also with an insight into B2B Life Sciences and alliance management.”
Read the full release here: https://biotec.no/news/biotec-pharmacon-appoints-new-ceo/